CCNE1 and endometrial cancer: Simpkins et al. identified oncogene Cyclin E1 (CCNE1) as the important biomarker for predicting responsiveness to low-dose WEE1i-ATRi combination in aggressive subsets of ovarian and endometrial cancers [71].